Next-generation sequencing impact on cancer care: applications, challenges, and future directions.

Autor:	Zalis M; Oncoclínicas&Co/MedSir, Rio de Janeiro, Brazil.; Medical School of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Viana Veloso GG; Oncoclínicas&Co/MedSir, Rio de Janeiro, Brazil.; Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil., Aguiar PN Jr; Oncoclínicas&Co/MedSir, Rio de Janeiro, Brazil.; Faculdade de Medicina do ABC, Santo André, Brazil., Gimenes N; Oncoclínicas&Co/MedSir, Rio de Janeiro, Brazil., Reis MX; Oncoclínicas&Co/MedSir, Rio de Janeiro, Brazil., Matsas S; Centro de Estudos e Pesquisas de Hematologia e Oncologia (CEPHO), Sao Paulo, Brazil., Ferreira CG; Oncoclínicas&Co/MedSir, Rio de Janeiro, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in genetics [Front Genet] 2024 Jul 09; Vol. 15, pp. 1420190. Date of Electronic Publication: 2024 Jul 09 (Print Publication: 2024).
DOI:	10.3389/fgene.2024.1420190
Abstrakt:	Fundamentally precision oncology illustrates the path in which molecular profiling of tumors can illuminate their biological behavior, diversity, and likely outcomes by identifying distinct genetic mutations, protein levels, and other biomarkers that underpin cancer progression. Next-generation sequencing became an indispensable diagnostic tool for diagnosis and treatment guidance in current clinical practice. Nowadays, tissue analysis benefits from further support through methods like comprehensive genomic profiling and liquid biopsies. However, precision medicine in the field of oncology presents specific hurdles, such as the cost-benefit balance and widespread accessibility, particularly in countries with low- and middle-income. A key issue is how to effectively extend next-generation sequencing to all cancer patients, thus empowering treatment decision-making. Concerns also extend to the quality and preservation of tissue samples, as well as the evaluation of health technologies. Moreover, as technology advances, novel next-generation sequencing assessments are being developed, including the study of Fragmentomics. Therefore, our objective was to delineate the primary uses of next-generation sequencing, discussing its' applications, limitations, and prospective paths forward in Oncology. Competing Interests: Authors MZ, GV, PA, NG, MR, and CF were employed by Oncoclínicas&Co/MedSir. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. GV and CF declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Zalis, Viana Veloso, Aguiar Jr., Gimenes, Reis, Matsas and Ferreira.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu